Fundraising FoxYonghua Capital — Full Portfolio
5 tracked investments · listed companies and verified rows first
Spear Bio develops high-sensitivity immunoassays based on its SPEAR (Successive Proximity Extension Amplification Reaction) technology, which originated from research at the Wyss Institute.
BiotechHealthtechMedical Devices
Feng Xuan(Chief Executive Officer & Co-founder)Peng Yin(Director & Co-Founder)
Co-investorsForesite CapitalMaverick Ventures
Miracor develops PiCSO (Pressure-controlled intermittent Coronary Sinus Occlusion), a therapy used during percutaneous coronary intervention (PCI) to treat acute myocardial infarction patients.
HealthtechMedical Devices
Co-investorsDelta PartnersMing capitalBek VenturesQuest for GrowthSHS Capital
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Co-investorsARCH Venture PartnersNorthpond Ventures6 Dimensions CapitalAlly Bridge GroupApplied VenturesKilonova Capital+3 more
Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients.
AI & Machine LearningBiotechHealthtechMedical DevicesAuburndale, US
Bob Langer(Director, Promoter)Dan Anderson(Executive Officer, Director, Promoter)inTatiana NovobrantsevainIgor FeldmaninWalter Capone(Executive Officer)Christine Bunt(Executive Officer, Director)in
Co-investors20/20 HealthCare Partners LLCHighlight Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.